2018 Investor Presentation

September 7, 2022
Amylyx Pharmaceuticals Stock Trading Halted Today
Second FDA Advisory Committee Meeting to Discuss NDA for AMX0035 for the Treatment of ALS CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 7, 2022-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Nasdaq has halted trading of the Company’s common stock....
July 6, 2022
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 6, 2022-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced a poster on the ongoing international Phase 3 PHOENIX trial (study A35-004, NCT05021536 ) of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also...
May 16, 2022
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
Adding to previously reported overall functional and survival benefit data for AMX0035, these findings support effect of AMX0035 on disease progression in ALS Randomization to AMX0035 resulted in a lower occurrence of death or tracheostomy/permanent assisted ventilation by 49% and first...
April 2, 2022
Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting
- Summary of data from CENTAUR and PEGASUS showed AMX0035 was safe and well tolerated in clinical trials in   amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) - Majority of treatment-emergent adverse events (TEAEs) associated with AMX0035 were gastrointestinal in both trials with no...
March 30, 2022
Amylyx Pharmaceuticals Stock Trading Halted Today
FDA Advisory Committee Meeting to Discuss NDA for AMX0035 for the Treatment of ALS CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 30, 2022-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Nasdaq has halted trading of the company’s common stock. The U.S....
February 16, 2022
Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 16, 2022-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that a virtual meeting of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee to review the New Drug Application (NDA) for AMX0035...
February 3, 2022
The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes for Canadians Living with ALS
CALGARY, Alberta & TORONTO--(BUSINESS WIRE)-- The Canadian Neuromuscular Disease Registry (CNDR), an independent, academic registry based out of the University of Calgary, and Amylyx Pharmaceuticals (NASDAQ: AMLX) today announced...